Research programme: antibody therapies - Paragon Therapeutics/Viridian Therapeutics
Latest Information Update: 16 May 2024
At a glance
- Originator Paragon Therapeutics
- Developer Viridian Therapeutics
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified